Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
A comprehensive invasive pneumococcal disease (IPD) laboratory surveillance program was carried out in Australia in 2003. This program provided data on the prevalence of pneumococcal serotypes and antimicrobial resistance. There were 1,995 isolates tested with 34 per cent (683) from children aged less than five years and 27 per cent (535) from the elderly aged more than 65 years. One thousand eight hundred and sixty were isolates from blood, 79 from CSF and 56 from other sterile sites. In young children, 84 per cent of isolates were a serotype and 92 per cent a serogroup in the 7-valent pneumococcal conjugate vaccine (7vPCV). Of penicillin resistant isolates in children less than five years of age 85 per cent and 98 per cent were a serotype and serogroup in the 7vPCV respectively. When the universal 7vPCV vaccine program in young children is introduced in 2005, a proportion of cases of IPD should also be prevented in young adults (estimated reduction of 54 cases annually) and elderly Australians (an estimated reduction of 110 cases annually) as a result of improved herd immunity. Pneumococcal serotypes with higher rates of penicillin resistance (19F, 14 and 6B) were more prevalent in the elderly than in young children. In contrast, erythromycin resistance was more common in children less than five years of age (24%) compared to the elderly (15%). The predominant serotype with erythromycin resistance in Australia was serotype 14 and thus there is likely to be a major reduction in erythromycin resistance as a result of 7vPCV vaccination. Continued surveillance of pneumococcal serotype distribution and antibiotic susceptibility will be essential in order to identify serotype replacement by non-vaccine serotypes and to monitor the overall impact of current and future vaccine programs on invasive pneumococcal disease in Australia, not only in young children but also in other age groups.
Watson
Michael
M
The NSW Pneumococcal Reference Laboratory, Department of Microbiology, The Children's Hospital at Westmead, Westmead, New South Wales. michael.watson@sjog.org.au
Roche
Paul
P
Bayley
Kathy
K
Bell
Jan M
JM
Collignon
Peter
P
Gilbert
Gwendolyn L
GL
Hogg
Geoff
G
Keil
Anthony D
AD
Krause
Vicki
V
Murphy
Denise
D
Smith
Helen V
HV
Brown
Mitchell
M
Stylianopoulos
Joanne
J
Turnidge
John
J
D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control*; D002675:Child, Preschool; D005260:Female; D005544:Forecasting; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D009517:New South Wales / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011159:Population Surveillance; D018570:Risk Assessment; D017678:Sex Distribution; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification*; D016019:Survival Analysis; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate